Literature DB >> 16763886

Clinical approach to treatable inborn metabolic diseases: an introduction.

J-M Saudubray1, F Sedel, J H Walter.   

Abstract

In view of the major improvements in treatment, it has become increasingly important that in order for first-line physicians not to miss a treatable disorder they should be able initiate a simple method of clinical screening, particularly in the emergency room. We present a simplified classification of treatable inborn errors of metabolism in three groups. Group 1 includes inborn errors of intermediary metabolism that give rise to an acute or chronic intoxication. It encompasses aminoacidopathies, organic acidurias, urea cycle disorders, sugar intolerances, metal disorders and porphyrias. Clinical expression can be acute or systemic or can involve a specific organ, and can strike in the neonatal period or later and intermittently from infancy to late adulthood. Most of these disorders are treatable and require the emergency removal of the toxin by special diets, extracorporeal procedures, cleansing drugs or vitamins. Group 2 includes inborn errors of intermediary metabolism that affect the cytoplasmic and mitochondrial energetic processes. Cytoplasmic defects encompass those affecting glycolysis, glycogenosis, gluconeogenesis, hyperinsulinisms, and creatine and pentose phosphate pathways; the latter are untreatable. Mitochondrial defects include respiratory chain disorders, and Krebs cycle and pyruvate oxidation defects, mostly untreatable, and disorders of fatty acid oxidation and ketone bodies that are treatable. Group 3 involves cellular organelles and includes lysosomal, peroxisomal, glycosylation, and cholesterol synthesis defects. Among these, some lysosomal disorders can be efficiently treated by enzyme replacement or substrate reduction therapies. Physicians can be faced with the possibility of a treatable inborn error in an emergency, either in the neonatal period or late in infancy to adulthood, or as chronic and progressive symptoms--general (failure to thrive), neurological, or specific for various organs or systems. These symptoms are summarized in four tables. In addition, an extensive list of medications used in the treatment of inborn errors is presented.

Entities:  

Mesh:

Year:  2006        PMID: 16763886     DOI: 10.1007/s10545-006-0358-0

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  11 in total

Review 1.  Inherited metabolic diseases and pregnancy.

Authors:  F J Spronsen; G P A Smit; J J H M Erwich
Journal:  BJOG       Date:  2005-01       Impact factor: 6.531

2.  Continuous mannose infusion in carbohydrate-deficient glycoprotein syndrome type I.

Authors:  E Mayatepek; M Schröder; D Kohlmüller; W P Bieger; W Nützenadel
Journal:  Acta Paediatr       Date:  1997-10       Impact factor: 2.299

3.  L-arginine improves the symptoms of strokelike episodes in MELAS.

Authors:  Y Koga; Y Akita; J Nishioka; S Yatsuga; N Povalko; Y Tanabe; S Fujimoto; Toyojiro Matsuishi
Journal:  Neurology       Date:  2005-02-22       Impact factor: 9.910

4.  Failure of short-term mannose therapy of patients with carbohydrate-deficient glycoprotein syndrome type 1A.

Authors:  S Kjaergaard; B Kristiansson; H Stibler; H H Freeze; M Schwartz; T Martinsson; F Skovby
Journal:  Acta Paediatr       Date:  1998-08       Impact factor: 2.299

Review 5.  Impact of diets and nutrients/drugs on early epigenetic programming.

Authors:  Claudine Junien
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

Review 6.  Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential.

Authors:  Charles R Roe; Fanny Mochel
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

Review 7.  Treatment with amino acids in serine deficiency disorders.

Authors:  T J de Koning
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

8.  Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3.

Authors:  Wen-Qi Zeng; Eiman Al-Yamani; James S Acierno; Susan Slaugenhaupt; Tammy Gillis; Marcy E MacDonald; Pinar T Ozand; James F Gusella
Journal:  Am J Hum Genet       Date:  2005-05-03       Impact factor: 11.025

9.  Transaldolase deficiency: a new cause of hydrops fetalis and neonatal multi-organ disease.

Authors:  Vassili Valayannopoulos; Nanda M Verhoeven; Karine Mention; Gajja S Salomons; Danièle Sommelet; Marie Gonzales; Guy Touati; Pascale de Lonlay; Cornelis Jakobs; Jean-Marie Saudubray
Journal:  J Pediatr       Date:  2006-11       Impact factor: 4.406

10.  Dilated cardiomyopathy due to type II X-linked 3-methylglutaconic aciduria: successful treatment with pantothenic acid.

Authors:  I Ostman-Smith; G Brown; A Johnson; J M Land
Journal:  Br Heart J       Date:  1994-10
View more
  29 in total

Review 1.  Acute management of propionic acidemia.

Authors:  Kimberly A Chapman; Andrea Gropman; Erin MacLeod; Kathy Stagni; Marshall L Summar; Keiko Ueda; Nicholas Ah Mew; Jill Franks; Eddie Island; Dietrich Matern; Loren Pena; Brittany Smith; V Reid Sutton; Tiina Urv; Charles Venditti; Anupam Chakrapani
Journal:  Mol Genet Metab       Date:  2011-09-24       Impact factor: 4.797

Review 2.  Neurological Disorders Associated with Striatal Lesions: Classification and Diagnostic Approach.

Authors:  Davide Tonduti; Luisa Chiapparini; Isabella Moroni; Anna Ardissone; Giovanna Zorzi; Federica Zibordi; Sergio Raspante; Celeste Panteghini; Barbara Garavaglia; Nardo Nardocci
Journal:  Curr Neurol Neurosci Rep       Date:  2016-06       Impact factor: 5.081

Review 3.  Treatment strategies for acute metabolic disorders in neonates.

Authors:  Sarar Mohamed
Journal:  Sudan J Paediatr       Date:  2011

4.  A Rare Cause of Sudden Onset- Severe Metabolic Acidosis in Paediatric Surgical Patients- Organic Acidemia.

Authors:  Vipin Kumar Singh; Rajeev Ratan Singh Yadav
Journal:  J Clin Diagn Res       Date:  2016-03-01

5.  Tricarboxylic acid cycle enzyme activities in a mouse model of methylmalonic aciduria.

Authors:  Parith Wongkittichote; Gary Cunningham; Marshall L Summar; Elena Pumbo; Patrick Forny; Matthias R Baumgartner; Kimberly A Chapman
Journal:  Mol Genet Metab       Date:  2019-10-17       Impact factor: 4.797

Review 6.  Fumaric aciduria: an overview and the first Brazilian case report.

Authors:  Gabriella Allegri; Marcia J Fernandes; Fernanda B Scalco; Patricia Correia; Ruth E Simoni; Juan C Llerena; Maria L Costa de Oliveira
Journal:  J Inherit Metab Dis       Date:  2010-06-15       Impact factor: 4.982

7.  Integration of metabolic and gene regulatory networks modulates the C. elegans dietary response.

Authors:  Emma Watson; Lesley T MacNeil; H Efsun Arda; Lihua Julie Zhu; Albertha J M Walhout
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

Review 8.  Patterns of brain injury in inborn errors of metabolism.

Authors:  Andrea L Gropman
Journal:  Semin Pediatr Neurol       Date:  2012-12       Impact factor: 1.636

Review 9.  Hereditary spastic paraparesis in adults associated with inborn errors of metabolism: a diagnostic approach.

Authors:  F Sedel; B Fontaine; J M Saudubray; O Lyon-Caen
Journal:  J Inherit Metab Dis       Date:  2007-10-22       Impact factor: 4.982

10.  Modulation of the activity of newly synthesized human phenylalanine hydroxylase mutant proteins by low-molecular-weight compounds.

Authors:  Cátia Nascimento; João Leandro; Isabel Tavares de Almeida; Paula Leandro
Journal:  Protein J       Date:  2008-09       Impact factor: 2.371

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.